Tirzepatide for Obesity Treatment and Diabetes Prevention
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. METHODS: We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods. RESULTS: At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo). Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001). After 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001). Other than coronavirus disease 2019, the most common adverse events were gastrointestinal, most of which were mild to moderate in severity and occurred primarily during the dose-escalation period in the first 20 weeks of the trial. No new safety signals were identified. CONCLUSIONS: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prediabetes to type 2 diabetes by 66-93% compared with placebo.65,75,76”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [76]
In the citing paper
“Tirzepatide administered at doses of 5, 10, and 15 mg once weekly in adjunct with a behavioral intervention comprising an energy-deficit diet and increased physical activity appears to be even more effective, with absolute weight losses of 15.0%, 19.5%, and 20.9% after 72 weeks in the SURMOUNT-1 trial 31 that was largely maintained when treatment was continued in a subset of participants for 176”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“SURMOUNT-1 showed the NNT with tirzepatide to prevent one case of T2D was 9 patients.”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“This stepwise approach anchored in trial evidence strengthens confidence in the validity and applicability of the current results, reinforcing the role of GLP-1-based therapies beyond previously established benefits in the evolving management of cardiometabolic HFpEF.54,56-62”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [62]
In the citing paper
“the reversal in glycemic benefits in HbA1c and FSG were observed early on within 16 weeks of withdrawing tirzepatide likely due to the known direct glucose-lowering effect of tirzepatide”
From Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial (2026) · cites this paper as [18]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citation2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Cited by
Items 401–443 of 443
Sattar, N. A., Mamas, M. A., Li, R., García‐Pérez, L., Chen, K. L., Upadhyay, N., Glass, L., Batterham, R. L., Dimitriadis, G. K., & Liu‐Seifert, H. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag408
Diabetes Update 2026 – Neue Studienergebnisse und Erkenntnisse
Scherbaum, W. A. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01486-3
Early Consideration of Automated Insulin Delivery in Type 2 Diabetes: A Critical Review
Tariq, Z., Aleppo, G., Carlson, A. L., Kayne, D. M., Kruger, D. F., Kudva, Y. C., Miller, E. M., O’Brien, K., Oser, S. M., Weinstock, R. S., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.005
Martínez‐Corral, I., Monaco, N., Brierley, D. I., & Imbernón, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70636 · Cited by 1
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
“Long-term tirzepatide treatment produced substantial, durable pharmacologic weight loss and reduced progression from prediabetes to type 2 diabetes (T2D) in people with obesity (12).”
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
“Tirzepatide 5–15 mg (Wadden et al., 2023; Jastreboff et al., 2022; Jastreboff et al., 2025; Salamah et al., 2024; Liu et al., Frontiers in Aging frontiersin.org 10 STEP-HFpEF (NEJM 2023) showed that semaglutide 2.4 mg improved symptoms (KCCQ-CSS) and exercise tolerance (6-min walk) over 52 weeks…”
InfluentialHe, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
“…need to give priority to patients at higher obesity-related risk, such as those with prediabetes, obstructive sleep apnea, cardiovascular disease, HFpEF, or other clinically important complications (Jastreboff et al., 2025; Malhotra et al., 2024; Loomba et al., 2024; Packer et al., 2025).”
Galindo, R. J., Dimitriadis, G. K., Stefański, A., et al. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag190
Self-citationVanlaer, Y., de Cauter, E. V., Embo, N., & Benhalima, K. (2026) · BMC Medicine · doi:10.1186/s12916-026-05182-3
“The primary objective is to determine whether semaglutide reduces progression to T2DM, providing the first robust evidence for pharmacological prevention in this population [59].”
InfluentialOlaniyi, A. O., Gogineni, K. K., Olaniyi, H., Sabir, H., Eboigbe, G. A., Yerima, S. R., & Gabriels, N. (2026) · Cureus · doi:10.7759/cureus.114962 · Cited by 1
“…potential for residual confounding, participant selection, and loss to follow-up, which are inherent limitations of non-randomised study designs [19-21 , The 15 prespecified secondary analyses originated from the included parent studies and therefore inherited the corresponding methodological…”
InfluentialRethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Montoye, A. H. K., Grosicki, G. J., Babcock, M. C., Fielding, F., von Hippel, W., Chapman, C. J., Henderson, D., Lee, V. H., & Holmes, K. E. (2026) · Journal of Sports Sciences · doi:10.1080/02640414.2026.2721858 · Cited by 1
Corrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes
Liao, K., Kuo, C.-Y., Wu, J., Hsu, W., Tsai, Y., & Lai, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1928877
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“Over three years in SUR-MOUNT-1, progression to type 2 diabetes occurred in 1.3% of obese prediabetic participants treated with tirz-epatide compared with 13.3% receiving placebo (hazard ratio 0.07) [44].”
InfluentialFrom Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity
Chen, H., Li, L., Zhang, J., Zhu, S., Cornier, M., & Purnell, J. Q. (2026) · Obesity · doi:10.1002/oby.70263
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Kow, C. S., Thiruchelvam, K., Ramachandram, D. S., & Zaihan, A. F. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70325 · Cited by 1
“The semaglutide subgroup included three studies [12, 14–15], three intervention arms, and 634 participants, while the tirzepatide subgroup included three studies [10–11, 13”
Prediabetes: Impact on cardiovascular risk and emerging therapeutic strategies
Biondi, F., Ghelardoni, S., Monti, E., Арманович, А. А., Caterina, R. D., & Madonna, R. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121898
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
“Clinical trials with up to 3–4 years' follow-up show that new incretin agents can facilitate sustained weight reduction and cardiometabolic benefits with continued treatment [39, 40].”
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
“Similarly, analysis of extended follow-up in the SURMOUNT-1 trial confirms longer-term sustained effects of tirzepatide evident over approximately 3 years in patients with obesity and prediabetes, with tirzepatide reducing progression to T2D by approximately 94% (158).”
Self-citationCardiovascular–Kidney–Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review
Enache, V., Popescu, D.-C., Marcu, B., Diaconu, M., & Nechita, A. C. (2026) · Medicina · doi:10.3390/medicina62091742
“Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, markedly reduced progression to T2DM in individuals with prediabetes and obesity or overweight after 176 weeks (1.3% vs. 13.3%; HR 0.07; 95% CI 0.0–0.1; p < 0.001), alongside substantial weight loss [107].”
InfluentialViana, D. P. D. C., Invitti, A. L., Jacobsen, L., & Schor, E. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109116
Kassem, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71293 · Cited by 2
Feng, Z., Lian, H., Liu, C., Shi, Y., He, C., Li, S., Liang, Q., & Li, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71348
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Gifford, R. M. (2026) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvag198
Shinde, S., Kahles, F., Vasileva-Metodiev, S. Z., Griffin, R. M., Liu‐Seifert, H., Lebrec, J., Xavier, N., Li, R., Klise, S. R., Singh, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71322 · Cited by 1
Aronne, L. J., Vincent, R. P., Klein, K. R., Brumm, J. F., Jouravskaya, I., Cao, D., Dimitriadis, G. K., & Dunn, J. P. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100333
“Over 90% of tirzepatide participants achieved and maintained normoglycemia at end of the study compared to 59% of placebo and 1.3% compared with 13.3% developed type 2 diabetes, respectively [11].”
InfluentialSelf-citationWaki, H., Kaneyuki, E., Shingaki, T., Oura, T., Nagakubo, T., & Ishigaki, Y. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.09.006
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
“Early response is the strongest available predictor, although late-response phenotypes are being characterized in the extension analyses of STEP-5 and SURMOUNT-1 in which a fraction of the participants who did not meet the 5% threshold at 6 months converted to responders by 12 to 18 months (67, 99).”
InfluentialKhan, M. M., Imam, H., Mondal, N. T., et al. (2025) · TAJ Journal of Teachers Association · doi:10.70818/taj.v38i04.0887
Carreiro, S. M., Ramos-Leví, A., Matía‐Martín, P., Madrid, B. B., Carrillo, C. R., Marcuello, C., Pérez‐Ferre, N., Torres-García, A. J., Sánchez-Pernaute, A., López-Jamar, J. M. E., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08954-1
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
Sakhnova, E. E., Gavrilova, N. A., Ostroumova, O. D., Кочетков, А. И., Telkova, S. S., & Moryakova, Y. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-324
Modern methods for the diagnosis and management of obesity
Александровна, М. О., Валерьевна, Г. Е., Эдуардовна, Т. М., Martirosian, N. S., Кузина, И. А., Алексеевич, Т. А., Petunina, N. A., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-296
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Self-citationTirzepatide: a new treatment for obesity - literature review
Correia, S., Pimenta, A. M., Souto, M. R. S., & Catarino, R. I. L. (2026) · Athena health & research journal. · doi:10.62741/ahrj.v3isuppl.2.199
Emerging Therapies in Diabetes: New Drugs and Innovative Remedies
bhavikkimar, P. P., Raval, A. M., Patel, H. B., Patel, K. H., Patel, P., & Prajapati, T. (2026) · Pharmacology and Toxicology Research · doi:10.68163/ptr.2026.61
“Lifestyle modifications, including dietary changes, exercise and behavioral support, remain the foundation of care, while metformin continues to be the first-line pharmacological treatment due to its efficacy and safety 9 .”
Sanchez-Navarro, M. J., Zhang, C., Fortin, S. M., & Hayes, M. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71415
Pînzariu, A. C., Șerban, I. L., Soroceanu, R. P., Vlăsceanu, V. I., Maxim, M., Miler, A. A., Leonte, S. M., Atodiresei, C., Moscalu, M., Manole, L. M., et al. (2026) · Cells · doi:10.3390/cells15191823
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Metadata
- Authors
- Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., & Jouravskaya, I.
- Affiliations
- University College Dublin (IE)
- Eli Lilly, Indianapolis
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-06
- Volume
- 392
- Issue
- 10
- Pages
- 958-971
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404310616
- Semantic Scholar
- 6522eecd15e4fbb48021d492e79ee341ffc3540a
- Cited by
- 462
- References
- 41
- Citations by year
- 2026: 239 · 2025: 220
- FWCI
- 130.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- tirzepatide, obesity, prediabetes, type 2 diabetes prevention, weight loss, GIP/GLP-1 receptor agonist, long-term safety, diabetes onset, adverse events, drug discontinuation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Obesity, Prediabetic State, Weight Loss, Disease Progression, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.